Virginia Regulatory Town Hall
Virginia Department of Health
State Board of Health
Prescription Drug Price Transparency Regulation [Under Development] [12 VAC 5 ‑ 219]
Promulgation of New Regulation to Implement Chapter 304 of the 2021 Acts of Assembly, Special Session I
General Information
Action Summary Chapter 304 (2021 Acts of Assembly, Special Session I) requires VDH to promulgate regulations to effectuate the act, specifically the specification of prescription drugs for the purpose of data collection and procedures for auditing information provided by health carriers, pharmacy benefits managers, wholesale distributors, and manufacturers, as well as a schedule of civil penalties for failure to report the information required, based on the severity of the violation. As the requirement to report prescription drug price information is new, there is no already existing regulatory chapter that would best fit this mandate, so VDH intends to promulgate a new regulatory chapter for these standards.
Chapters Affected Only affects this chapter.
Executive Branch Review This action will go through the normal Executive Branch Review process.
RIS Project Yes  [6828]
Associated Mandates Promulgate regulations related to prescription drug pricing transparency reporting
New Periodic Review This action will not be used to conduct a new periodic review.
Stages associated with this regulatory action.
Stage ID Stage Type Status
9393 Emergency/NOIRA Stage complete. Emergency regulation was set to expire on 07/16/2023 and has been extended until 01/15/2024.
9814 Proposed Secretary of Health and Human Resources review in progress.
Contact Information
Name / Title: Michael Sarkissian  / Director, Data and Quality
Address: Virginia Department of Health
109 Governor Street
Richmond, VA 23219
Email Address:
Phone: (804)864-7416    FAX: (804)864-7022    TDD: ()-